Swedish Orphan Biovitrum AB (publ) (LON: 0MTD)

Market Cap	8.52B
Revenue (ttm)	1.87B
Net Income (ttm)	258.50M
Shares Out	n/a
EPS (ttm)	0.74
PE Ratio	32.96
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	29,020
Average Volume	73,614
Open	331.30
Previous Close	333.40
Day's Range	329.40 - 339.60
52-Week Range	17.57 - 25.61
Beta	0.23
RSI	64.39
Earnings Date	Feb 5, 2025

About Swedish Orphan Biovitrum AB

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1939
• Employees: 1,772
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0MTD

Financial Performance

In 2023, Swedish Orphan Biovitrum AB's revenue was 22.12 billion, an increase of 17.74% compared to the previous year's 18.79 billion. Earnings were 2.41 billion, a decrease of -8.68%.

Financial numbers in SEK